These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 6357232)

  • 41. A PROPOSED MICROBIOLOGICAL METHOD FOR STUDYING THE STABILITY OF PRESERVATIVES IN PARENTERAL SOLUTIONS.
    EISMAN PC; JACONIA D; LAZARUS J
    Bull Parenter Drug Assoc; 1963; 17():10-7. PubMed ID: 14059429
    [No Abstract]   [Full Text] [Related]  

  • 42. Stabilizers for parenteral drugs.
    Scheindlin S
    Bull Parenter Drug Assoc; 1966; 20(2):61-4. PubMed ID: 5905230
    [No Abstract]   [Full Text] [Related]  

  • 43. Pharmaceutical specialties in the U.S.--a note about the PDR 1972.
    Du Souich P; Erill S; Garcia-Sevilla JA
    J Clin Pharmacol; 1974 Jul; 14(7):325-8. PubMed ID: 4846394
    [No Abstract]   [Full Text] [Related]  

  • 44. Drug delivery for optimised products: from product life-cycle management to first-generation product concepts.
    Bhatt PP
    Expert Opin Drug Deliv; 2005 Jan; 2(1):1-2. PubMed ID: 16296731
    [No Abstract]   [Full Text] [Related]  

  • 45. Preformulation stability testing of parenteral products.
    Zoglio MA
    Bull Parenter Drug Assoc; 1968; 22(6):295-8. PubMed ID: 5727165
    [No Abstract]   [Full Text] [Related]  

  • 46. Evaluation of the pharmaceutical quality of some quinine preparations sold in Nigeria.
    Nnamdi JA; Arhewoh IM; Okhamafe AO; Enato EF
    Med Princ Pract; 2009; 18(3):193-7. PubMed ID: 19349721
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Biopharmaceutical study of new oral dosage forms of indomethacin].
    Aiache JM; Roca R; Bastide J; Bastide M; Kantelip JP
    J Pharm Belg; 1983; 38(1):5-21. PubMed ID: 6864434
    [No Abstract]   [Full Text] [Related]  

  • 48. The impact of primary packaging on the quality of parenteral products.
    Solomun L; Ibric S; Boltic Z; Djuric Z; Stupar B
    J Pharm Biomed Anal; 2008 Nov; 48(3):744-8. PubMed ID: 18786797
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Possibilities and problems of organ-selective active principles and drugs].
    Hamacher H
    Pharmazie; 1981 Jun; 36(6):391-9. PubMed ID: 7025022
    [No Abstract]   [Full Text] [Related]  

  • 50. The basis for selection of the dosage form and source of a drug.
    Levy G; Barr WH
    Ration Drug Ther; 1972 Jan; 6(1):1-7. PubMed ID: 5084612
    [No Abstract]   [Full Text] [Related]  

  • 51. Formulation of medicines for children.
    Nunn T; Williams J
    Br J Clin Pharmacol; 2005 Jun; 59(6):674-6. PubMed ID: 15948931
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Drugs and the organism. II. Bioavailability].
    Pflegel P; Pfeifer S
    Pharmazie; 1980; 34(5-6):337-59. PubMed ID: 6893363
    [No Abstract]   [Full Text] [Related]  

  • 53. Pharmaceutical product development technologies based on the biopharmaceutical classification system.
    Jain D; Pathak D; Pathak K
    Pharmazie; 2009 Aug; 64(8):483-90. PubMed ID: 19746834
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Dosage calculations for drugs administered by infusion.
    Zenk KE
    Am J Hosp Pharm; 1980 Oct; 37(10):1304-5. PubMed ID: 7424921
    [No Abstract]   [Full Text] [Related]  

  • 55. A century of dissolution research: from Noyes and Whitney to the biopharmaceutics classification system.
    Dokoumetzidis A; Macheras P
    Int J Pharm; 2006 Sep; 321(1-2):1-11. PubMed ID: 16920290
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Drug preparations of proton pump inhibitors].
    Breitkreutz J
    Pharm Unserer Zeit; 2005; 34(3):216-23. PubMed ID: 15940955
    [No Abstract]   [Full Text] [Related]  

  • 57. [Analysis of the items of pharmaceutics of Chinese medicine accepted and supported by NSFC in recent 5 years].
    Han LW; Wang CE; Liu P; Ju DH
    Zhongguo Zhong Yao Za Zhi; 2004 Jan; 29(1):4-6. PubMed ID: 15709369
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Photostability of parenteral chemotheraphy admixtures.
    Siderov J; Stevenson B
    J Oncol Pharm Pract; 2007 Dec; 13(4):231. PubMed ID: 18045782
    [No Abstract]   [Full Text] [Related]  

  • 59. [Galenical preparations from lycopodium oil (author's transl)].
    Pourrat A; Renoux R; Pourrat H; Carnat AP
    J Pharm Belg; 1980; 35(3):226-32. PubMed ID: 7400927
    [No Abstract]   [Full Text] [Related]  

  • 60. [On the use of sorbitol in the production of infusion solutions].
    Dittmer HH; Trekel D
    Pharm Prax; 1965; 9():206-8. PubMed ID: 5888288
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.